This trial is evaluating whether MTM + ILI will improve 1 primary outcome, 14 secondary outcomes, and 42 other outcomes in patients with Diabetes Mellitus, Type 2. Measurement will happen over the course of 6 months.
This trial requires 200 total participants across 2 different treatment groups
This trial involves 2 different treatments. MTM + ILI is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The prevalence of diabetes in the US is 20.1%. Approximately 29 million adults have diabetes. With 1 in 3 adults in the US having diabetes, healthcare and public investment on diabetes continue to be large. Diabetes in the US is caused by a complex interaction of a number of environmental and genetic factors.\n" - Anonymous Online Contributor
"Diabetes mellitus type 2 may present with a myriad of clinical complaints. A person with diabetes mellitus type 2 is at increased risk of developing complications and is likely to present with acute symptoms that may mimic acute heart disease and neurological symptoms." - Anonymous Online Contributor
"Results from a recent paper suggests that about 80% to 90% of Americans will develop diabetes by age 55. Diabetes is not just a problem for the nation as a whole because individuals from the highest ethnic and socioeconomic groups are at greatest risk." - Anonymous Online Contributor
"Diabetes, type 2 cannot be cured. It becomes an incurable disease when it progresses to complications. And, many patients with [type 2 diabetes](https://www.withpower.com/clinical-trials/type-2-diabetes) can live with no or very mild symptoms." - Anonymous Online Contributor
"Effective, affordable medical treatments exist for diabetic foot ulcers (DFUs) and lower extremity neuropathy, and for other cardiovascular complications. Because of their effectiveness, proper referral, and affordability, medical management often yields a durable functional outcome as well as improved clinical status. These treatments may also decrease disease-related morbidity and mortality. We anticipate that improved treatment will decrease the prevalence of DFUs and lower extremity neuropathy." - Anonymous Online Contributor
"It is clear that genetic and environmental factors are involved in the development of diabetes mellitus, type 2. There is evidence that the disorder may be associated with the consumption of alcohol but there is no direct causal relationship." - Anonymous Online Contributor
"Patients with Mtm+ili are no more likely to have diabetes or heart disease compared with people who do not have the mutation. The risk of pancreatitis may be greater when pancreatitis occurs, but the risk is still low. It is also possible that the mutation causes an increased risk for developing a type of cancers, especially pancreas cancer, but this is still uncertain." - Anonymous Online Contributor
"Results indicate that the genetic basis for diabetes mellitus in American Indian families is predominantly genetically based rather than being a result of a defect in the action or utilization of the insulin pathway." - Anonymous Online Contributor
"This meta-analysis has identified important treatment differences in type 1 and type 2 DM between patients who receive insulin and those who do not, which could have a significant impact on the health-care system, on resource usage and the overall effectiveness of diabetes. Data from a recent study warrant more in-depth analyses to find the most effective treatment strategy to reduce morbidity in diabetic patients. Data from a recent study, therefore, could prompt a discussion regarding the need for a structured and well-designed clinical trial, focusing on patients with type 1 and type2 DM, for evaluating this issue." - Anonymous Online Contributor
"The average age that diabetes mellitus, type 2 occurs among whites with high or low BMI and high or low triglyceride levels is 5 and 19 years old, respectively." - Anonymous Online Contributor
"MTM + ili (MMT + DM + MI): Side effects are as follows: headache, dizziness, dizziness, weakness. It is important to follow the above-mentioned side effects by a healthcare provider(e.g. doctor) for further investigation and treatment.\n" - Anonymous Online Contributor
"At the present time there are no clinical trials for patients diagnosed with type 2 Diabetes and MTM2 mutation. Further studies should be undertaken for patients who have different clinical and histological manifestations and for patients with different genetic variants, with and without an iliac crest bone biopsy." - Anonymous Online Contributor